The chronic control of tumor growth by a well-tolerated, oral compound would be desirable in the elderly and in asymptomatic individuals at high risk for cancer. Angiogenesis is recognized as an important determinant in tumor development and progression which is not prominent in normal tissues. Copper depletion has been shown to lead to smaller, largely avascular tumors, in animal models of implanted tumors. However, the large size of the implanted tumors used in previous studies may have prevented the detection of any survival benefit due to copper depletion. We hypothesize that oral Tetrathiomolybdate (TM) , the most potent and safest inhibitor of blood copper known (used in humans with Wilson's disease), will retard the onset and/or slow down the growth of mammary tumors in cancer prone Her2/neu+ transgenic mice by an anti-angiogenic mechanism. Preliminary data from our laboratory indicate that long-term administration of TM is safe and effective in the Her2/neu transgenic mouse in completely preventing the appearance of clinically significant tumors. In this application we propose to study TM's effect on angiogenesis in 3 in vivo models: the Her2/neu transgenic mice, the Dunning's rat prostate cancer model, and implanted lung cancer xenografts in SCID mice. The cells from these models will be used in in vitro experiments to test the hypothesis that TM interferes with VEGF secretion and action and angiogenic chemokine IL-6 and IL-8 function. This work will help uncover the molecular events whereby TM affects signaling of the angiogenic switch in cancer. By defining the molecular basis of TM's inhibition of angiogenesis, this work will help tailor the clinical application of TM in cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA077612-04
Application #
6513363
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Wolpert, Mary K
Project Start
1999-07-16
Project End
2003-04-30
Budget Start
2002-05-01
Budget End
2003-04-30
Support Year
4
Fiscal Year
2002
Total Cost
$237,244
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Wynn, Michelle L; Consul, Nikita; Merajver, Sofia D et al. (2012) Logic-based models in systems biology: a predictive and parameter-free network analysis method. Integr Biol (Camb) 4:1323-37
Wynn, Michelle L; Merajver, Sofia D; Schnell, Santiago (2012) Unraveling the complex regulatory relationships between metabolism and signal transduction in cancer. Adv Exp Med Biol 736:179-89
Wynn, Michelle L; Ventura, Alejandra C; Sepulchre, Jacques A et al. (2011) Kinase inhibitors can produce off-target effects and activate linked pathways by retroactivity. BMC Syst Biol 5:156
Rosenthal, Devin T; Iyer, Harish; Escudero, Silvia et al. (2011) p38? promotes breast cancer cell motility and metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a novel leading edge behavior. Cancer Res 71:6338-49
Soliman, Amr S; Kleer, Celina G; Mrad, Karima et al. (2011) Inflammatory breast cancer in north Africa: comparison of clinical and molecular epidemiologic characteristics of patients from Egypt, Tunisia, and Morocco. Breast Dis 33:159-69
Wu, Mei; Wu, Zhi-Fen; Rosenthal, Devin T et al. (2010) Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancers. Cancer 116:2768-82
Kumar, Pawan; Yadav, Arti; Patel, Samip N et al. (2010) Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis. Mol Cancer 9:206
Ventura, Alejandra C; Jiang, Peng; Van Wassenhove, Lauren et al. (2010) Signaling properties of a covalent modification cycle are altered by a downstream target. Proc Natl Acad Sci U S A 107:10032-7
Iniesta, Maria D; Gorin, Michael A; Chien, Ling-Chen et al. (2010) Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America. Cancer Genet Cytogenet 202:136-40
Varedi K, S Marjan; Ventura, Alejandra C; Merajver, Sofia D et al. (2010) Multisite phosphorylation provides an effective and flexible mechanism for switch-like protein degradation. PLoS One 5:e14029

Showing the most recent 10 out of 64 publications